Bioxytran, Inc (BIXT) stock
BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Bioxytran r&d expenses
Research and development expenses are spending on new products and technology.
Bioxytran's R&D Expenses for the twelve months ending Jun 30, 2026 was $482.96K, down 10.1% year over year. For fiscal 2025 it was $454.00K, up 304.1% from the year before. The highest annual figure on record is $2.01M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $454.00K | +304.1% |
| FY2024 | Dec 31, 2024 | $112.34K | -90.2% |
| FY2023 | Dec 31, 2023 | $1.15M | -10.1% |
| FY2022 | Dec 31, 2022 | $1.28M | -36.5% |
| FY2021 | Dec 31, 2021 | $2.01M | +269.8% |
| FY2020 | Dec 31, 2020 | $544.52K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $255.48K | +149.2% |
| Q1 FY2026 | Mar 31, 2026 | $225.48K | -35.5% |
| Q4 FY2025 | Dec 31, 2025 | $2.00K | -94.2% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $102.50K | – |
| Q1 FY2025 | Mar 31, 2025 | $349.50K | +1194.4% |
| Q4 FY2024 | Dec 31, 2024 | $34.34K | -93.7% |
| Q3 FY2024 | Sep 30, 2024 | $51.00K | -83.9% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $27.00K | -80.6% |
| Q4 FY2023 | Dec 31, 2023 | $544.44K | +5.0% |
| Q3 FY2023 | Sep 30, 2023 | $316.13K | -33.6% |
| Q2 FY2023 | Jun 30, 2023 | $149.64K | +246.9% |
| Q1 FY2023 | Mar 31, 2023 | $139.00K | -42.1% |
| Q4 FY2022 | Dec 31, 2022 | $518.63K | -32.3% |
| Q3 FY2022 | Sep 30, 2022 | $475.87K | +161.5% |
| Q2 FY2022 | Jun 30, 2022 | $43.14K | -94.0% |
| Q1 FY2022 | Mar 31, 2022 | $240.13K | -30.8% |
| Q4 FY2021 | Dec 31, 2021 | $766.12K | – |
| Q3 FY2021 | Sep 30, 2021 | $181.96K | – |
| Q2 FY2021 | Jun 30, 2021 | $718.65K | – |
| Q1 FY2021 | Mar 31, 2021 | $347.03K | – |
See a number that looks wrong?